Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28502618 | 1.00 | GAA (0.43) | GAAABCB1TSHRBCHEPTGES2 | |
| SCHEMBL28499108 | 0.92 | BCHE (0.40) | GAAABCB1TSHRBCHEPTGES2 | |
| SCHEMBL14769887 | 0.86 | GAA (0.43) | GAAABCB1TSHRBCHEPTGES2 | |
| SCHEMBL28336618 | 0.86 | GAA (0.43) | GAAABCB1TSHRBCHEPTGES2 | |
| SCHEMBL28403240 | 0.85 | GAA (0.42) | GAAABCB1TSHRBCHEPTGES2 | |
| SCHEMBL14769874 | 0.83 | GAA (0.40) | GAAABCB1TSHRBCHEKMT2A | |
| SCHEMBL28412125 | 0.83 | ABCB1 (0.44) | GAAABCB1TSHRKMT2ASLC43A1 | |
| SCHEMBL28716091 | 0.81 | NPC1 (0.40) | GAAABCB1BCHEKMT2AMEN1 | |
| SCHEMBL24371811 | 0.81 | ALDH1A1 (0.50) | GAAKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL16576338 | 0.81 | ALDH1A1 (0.50) | GAAKMT2AMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-8951985-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951985-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130064793-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130064793-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064793-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | GAA 77/4885ABCB1 1029/4885TSHR 4825/4885 |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | PYGL, HAVCR2, PNP | GAA 141/4885ABCB1 2216/4885TSHR 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.